BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Recruiting · Phase 1 · NCT06756932

Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer

Research payments reported, 2025: $226,010
U.S. investigators named: 5
Sites paid: 4
Planned or actual enrollment: 120

About the trial

Sponsor: BeOne Medicines
Tested: BGB-21447 (drug), Fulvestrant (drug), BGB-43395 (drug)
Dates: Started 2025-02-04; completion 2027-07-30
Results posted: Not yet

This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.

From ClinicalTrials.gov, last updated 2026-09-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Beone Medicines Ltd. reported $226,010 in research payments for this study in 2025 (29 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Ut MD Anderson Cancer Center $164,216
Hoag Memorial Hospital Presbyterian $35,352
University of Iowa Hospital & Clinics, IA $14,415
Fred Hutchinson Cancer Research Center $12,028

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it